{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-22-010347","form_type":"8-K","ticker":"AURX","cik":"0001091596","company_name":"Nuo Therapeutics, Inc.","filed_at":"2022-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.706772+00:00","generated_at":"2026-06-26T01:54:10.495036+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Nuo Therapeutics raises $3.55M in private placement at $1.00/share with insider participation","bullets":["Sold 3,550,000 shares of common stock at $1.00 per share for gross proceeds of $3,550,000.","Insider investors include CEO/CFO David Jorden ($10,532), director Scott Pittman ($100,000), COO Peter Clausen ($25,000), and principal holder Charles Sheedy ($804,868).","Proceeds to be used for working capital; post-offering shares outstanding increase to 40,674,205.","Shares issued under Section 4(a)(2) and Rule 506 in unregistered transaction; company not current in SEC reports."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-22-010347","json":"https://secwatch.observer/filing/0001437749-22-010347.json","markdown":"https://secwatch.observer/filing/0001437749-22-010347.md","text":"https://secwatch.observer/filing/0001437749-22-010347.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1091596/000143774922010347/0001437749-22-010347-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1091596/000143774922010347/aurx20220427_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T01:54:10.495036+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}